 "Strides Arcolab gains on USFDA nod for Lamivudine and Zidovudine tablets")
Shares of Strides Arcolab were trading higher by 4% to Rs 1,069 on the NSE after a pharmaceutical company said that it has received approval from the US health regulator for Lamivudine and Zidovudine tablets.
“The company has received approval from US Food and Drug Administration (USFDA) for Lamivudine and Zidovudine tablets in strengths of 150 and 300 mg”, Strides Arcolab said in a statement.
Lamivudine and Zidovudine tablets belong to a group of antiviral medicines, also known as antiretrovirals and used to treat Human Immunodeficiency Virus (HIV) infection.
The company said, the product will be manufactured at the company's oral dosage facility at Bangalore and marked by Strides in the US Market. The product will be launched in the markets immediately.
According to IMS data, the US market for Lamivudine and Zidovudine tablets is approximately $120 million, it added.
The stock opened at Rs 1,043 and touched high of Rs 1,077 on the NSE. A combined 485,191 shares changed hands on the counter on the NSE and BSE till 1119 hours.
“The company has received approval from US Food and Drug Administration (USFDA) for Lamivudine and Zidovudine tablets in strengths of 150 and 300 mg”, Strides Arcolab said in a statement.
Lamivudine and Zidovudine tablets belong to a group of antiviral medicines, also known as antiretrovirals and used to treat Human Immunodeficiency Virus (HIV) infection.
The company said, the product will be manufactured at the company's oral dosage facility at Bangalore and marked by Strides in the US Market. The product will be launched in the markets immediately.
According to IMS data, the US market for Lamivudine and Zidovudine tablets is approximately $120 million, it added.
The stock opened at Rs 1,043 and touched high of Rs 1,077 on the NSE. A combined 485,191 shares changed hands on the counter on the NSE and BSE till 1119 hours.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%